Immunogenicity of recombinant human rotavirus VP6 structural protein from Egyptian isolates and inactivated virus as candidate vaccines.

Abstract

Rotavirus (RoV) causes severe gastroenteritis in children under 5 years of age with high mortality and morbidity rates especially in low and middle income countries. Two licensed live oral RoV vaccines (pentavalent RotaTeq® and monovalent Rotarix®) are commercially available. However, several studies demonstrated that these oral commercial vaccines are less effective in developing immunity and did not cover all human rotavirus G and p types. Also, there is a risk of introduction of vaccine strains into the environment, genetic reassortment between the vaccine and a wild-type strain, and reversion of the vaccine strain toward virulence. Therefore, in the present study two non-living vaccines candidates were developed and tested for their immunogenicity against rotavirus.